Literature DB >> 19181792

Cryptochrome-1 expression: a new prognostic marker in B-cell chronic lymphocytic leukemia.

Eloisa Jantus Lewintre1, Cristina Reinoso Martín, Carlos García Ballesteros, David Montaner, Rosa Farrás Rivera, José Ramón Mayans, Javier García-Conde.   

Abstract

Chronic lymphocytic leukemia is an adult-onset leukemia with a heterogeneous clinical behavior. When chronic lymphocytic leukemia cases were divided on the basis of IgV(H) mutational status, widely differing clinical courses were revealed. Since IgV(H) sequencing is difficult to perform in a routine diagnostic laboratory, finding a surrogate for IgV(H) mutational status seems an important priority. In the present study, we proposed the use of Cryptochrome-1 as a new prognostic marker in early-stage chronic lymphocytic leukemia. Seventy patients (Binet stage A, without treatment) were included in the study. We correlated Cryptochrome-1 mRNA with well established prognostic markers such as IgV(H) mutations, ZAP70, LPL or CD38 expression and chromosomal abnormalities. High Cryptochrome-1 expression correlated with IgV(H) unmutated samples. In addition, Cryptochrome-1 was a valuable predictor of disease progression in early-stage chronic lymphocytic leukemia, therefore it can be introduced in clinical practice with the advantage of a simplified method of quantification.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19181792      PMCID: PMC2635393          DOI: 10.3324/haematol.13052

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  23 in total

1.  Clinical staging of chronic lymphocytic leukemia.

Authors:  K R Rai; A Sawitsky; E P Cronkite; A D Chanana; R N Levy; B S Pasternack
Journal:  Blood       Date:  1975-08       Impact factor: 22.113

2.  Circadian clock genes oscillate in human peripheral blood mononuclear cells.

Authors:  Diane B Boivin; Francine O James; Aibin Wu; Park F Cho-Park; Huabao Xiong; Zhong S Sun
Journal:  Blood       Date:  2003-07-31       Impact factor: 22.113

3.  National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment.

Authors:  B D Cheson; J M Bennett; M Grever; N Kay; M J Keating; S O'Brien; K R Rai
Journal:  Blood       Date:  1996-06-15       Impact factor: 22.113

4.  A clinical staging system for chronic lymphocytic leukemia: prognostic significance.

Authors:  J L Binet; M Leporrier; G Dighiero; D Charron; P D'Athis; G Vaugier; H M Beral; J C Natali; M Raphael; B Nizet; J Y Follezou
Journal:  Cancer       Date:  1977-08       Impact factor: 6.860

Review 5.  Novel therapies for chronic lymphocytic leukemia in the 21st century.

Authors:  J C Byrd; J K Waselenko; M Keating; K Rai; M R Grever
Journal:  Semin Oncol       Date:  2000-10       Impact factor: 4.929

6.  ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia.

Authors:  Marta Crespo; Francesc Bosch; Neus Villamor; Beatriz Bellosillo; Dolors Colomer; María Rozman; Silvia Marcé; Armando López-Guillermo; Elies Campo; Emili Montserrat
Journal:  N Engl J Med       Date:  2003-05-01       Impact factor: 91.245

Review 7.  Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936.

Authors:  J J M van Dongen; A W Langerak; M Brüggemann; P A S Evans; M Hummel; F L Lavender; E Delabesse; F Davi; E Schuuring; R García-Sanz; J H J M van Krieken; J Droese; D González; C Bastard; H E White; M Spaargaren; M González; A Parreira; J L Smith; G J Morgan; M Kneba; E A Macintyre
Journal:  Leukemia       Date:  2003-12       Impact factor: 11.528

8.  Routine analysis of IgVH mutational status in CLL patients using BIOMED-2 standardized primers and protocols.

Authors:  Christine Matthews; Mark Catherwood; T C M 'Curly' Morris; H Denis Alexander
Journal:  Leuk Lymphoma       Date:  2004-09

9.  Analysis of chronic lymphotic leukemia transcriptomic profile: differences between molecular subgroups.

Authors:  Eloisa Jantus Lewintre; Cristina Reinoso Martín; David Montaner; Miguel Marín; María José Terol; Rosa Farrás; Isabel Benet; Juan J Calvete; Joaquín Dopazo; Javier García-Conde
Journal:  Leuk Lymphoma       Date:  2009-01

10.  Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia.

Authors:  A Rosenwald; A A Alizadeh; G Widhopf; R Simon; R E Davis; X Yu; L Yang; O K Pickeral; L Z Rassenti; J Powell; D Botstein; J C Byrd; M R Grever; B D Cheson; N Chiorazzi; W H Wilson; T J Kipps; P O Brown; L M Staudt
Journal:  J Exp Med       Date:  2001-12-03       Impact factor: 14.307

View more
  8 in total

1.  Weak radiofrequency fields affect the insect circadian clock.

Authors:  Premysl Bartos; Radek Netusil; Pavel Slaby; David Dolezel; Thorsten Ritz; Martin Vacha
Journal:  J R Soc Interface       Date:  2019-09-18       Impact factor: 4.118

Review 2.  Understanding the significance of biological clock and its impact on cancer incidence.

Authors:  Shalie Malik; James Stokes Iii; Upender Manne; Rajesh Singh; Manoj K Mishra
Journal:  Cancer Lett       Date:  2021-12-11       Impact factor: 8.679

3.  Cryptochrome 1 Alleviates the Antiproliferative Effect of Isoproterenol on Human Gastric Cancer Cells.

Authors:  Qianwu Huang; Jun Lv; Ting Dong; Haijun Liu; Lei Xu; Mingcai Wu
Journal:  Dose Response       Date:  2020-07-09       Impact factor: 2.658

4.  Circadian rhythm and its role in malignancy.

Authors:  Sobia Rana; Saqib Mahmood
Journal:  J Circadian Rhythms       Date:  2010-03-31

Review 5.  The circadian clock in cancer development and therapy.

Authors:  Loning Fu; Nicole M Kettner
Journal:  Prog Mol Biol Transl Sci       Date:  2013       Impact factor: 3.622

6.  Epigenetic silencing of the circadian clock gene CRY1 is associated with an indolent clinical course in chronic lymphocytic leukemia.

Authors:  Maher Hanoun; Lewin Eisele; Masako Suzuki; John M Greally; Andreas Hüttmann; Semra Aydin; René Scholtysik; Ludger Klein-Hitpass; Ulrich Dührsen; Jan Dürig
Journal:  PLoS One       Date:  2012-03-28       Impact factor: 3.240

7.  Interphase fluorescence in situ hybridization analysis of CD19-selected cells: Utility in detecting disease in post-therapy samples of B-cell neoplasms.

Authors:  Andrew M Parrott; Vundavalli V Murty; Caitlin Walsh; Alecia Christiano; Govind Bhagat; Bachir Alobeid
Journal:  Cancer Med       Date:  2021-03-15       Impact factor: 4.452

8.  Cryptochrome-1 Gene Expression is a Reliable Prognostic Indicator in Egyptian Patients with Chronic Lymphocytic Leukemia: A Prospective Cohort Study

Authors:  Deena Mohamed Habashy; Deena Samir Eissa; Mona Mahmoud Aboelez
Journal:  Turk J Haematol       Date:  2017-09-08       Impact factor: 1.831

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.